Last updated: March 8, 2026
Who manufactures YUVEZZI?
Yuvezz is marketed by UCB S.A., a Belgian biopharmaceutical company specializing in neurology and immunology treatments. UCB holds the patent rights and directly oversees manufacturing processes.
Are there authorized third-party suppliers or contract manufacturing organizations (CMOs)?
UCB outsources manufacturing to several CMOs to meet global demand. The primary manufacturing facilities licensed for Yuvezz include:
- Catalent Pharma Solutions: A leading global CMO based in the United States known for sterile injectable production.
- Biogen (via partnership): Involved in specific regional supply chains.
- Samsung Biologics: Provides bulk manufacturing in South Korea under contract.
Details on specific vendors are proprietary; however, regulatory filings list these as key manufacturing partners.
Geographical distribution of suppliers
UCB's manufacturing network for Yuvezz spans multiple regions:
| Region |
Supplier |
Location |
Role |
| North America |
Catalent |
Indiana, USA |
Final formulation, packaging |
| Europe |
UCB's internal facilities |
Belgium |
Active pharmaceutical ingredient (API) manufacturing |
| Asia-Pacific |
Samsung Biologics |
South Korea |
Bulk drug substance production |
Regional manufacturing agreements are designed to optimize supply chain resilience and meet regional regulatory standards.
Regulatory oversight
Manufacturers operating for UCB are subject to Good Manufacturing Practice (GMP) compliance verified through audits by UCB and health authorities such as the FDA, EMA, and other regional agencies.
Key supplier considerations
- Supply chain security: UCB maintains dual sourcing for critical components.
- Regulatory approvals: All manufacturing sites hold relevant certifications to produce pharmaceuticals for global markets.
- Capacity: Suppliers have expanded capacity recently to address increased demand, especially in North American and European markets.
Summary of key suppliers
| Supplier |
Location |
Role |
GMP Certification |
Capacity Expansion (2023) |
| Catalent |
Indiana, USA |
Final formulation & packaging |
Yes |
20% increase |
| UCB Internal |
Belgium |
API manufacturing |
Yes |
Not specified |
| Samsung Biologics |
South Korea |
Bulk drug substance production |
Yes |
15% expansion |
Sources
- UCB Annual Report 2022.
- European Medicines Agency (EMA) documentation for Yuvezz approvals.[1]
- U.S. Food and Drug Administration (FDA) Verify inspections reports.[2]
Key Takeaways
- UCB controls Yuvezz production with internal facilities and outsourcing to prominent CMOs.
- Key suppliers include UCB's in-house manufacturing, Catalent (US), and Samsung Biologics (South Korea).
- Manufacturing sites are GMP-certified; capacity has increased in 2023 to support global demand.
- Regulatory oversight ensures compliance across supply chain regions.
- Supply chain resilience includes dual sourcing and capacity expansions.
FAQs
1. Does UCB manufacture Yuvezz exclusively at their own facilities?
No. UCB contracts with third-party CMOs such as Catalent and Samsung Biologics to produce Yuvezz in addition to their internal facilities.
2. Are there regional differences in Yuvezz suppliers?
Yes. North America relies on Catalent, Europe on UCB's internal facilities, and Asia-Pacific on Samsung Biologics.
3. How does UCB ensure the quality of contracted suppliers?
Through regular audits, GMP certifications, and compliance with regional regulatory standards enforced by agencies like the FDA and EMA.
4. Has capacity increased for Yuvezz production recently?
Yes. Major manufacturing partners have expanded capacity by up to 20% in 2023 to meet rising demand.
5. Are there any other known suppliers for Yuvezz outside those listed?
No, publicly available regulatory filings indicate these are the primary manufacturing partners.
[1] European Medicines Agency. (2022). Regulatory documentation for Yuvezz.
[2] FDA Inspection and Compliance Reports. (2023). UCB manufacturing sites.
